HealthDay News — For patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), the combination of anastrozole, palbociclib, ...

Concomitant idiopathic pulmonary fibrosis (IPF) and lung cancer are associated with a substantially higher risk of mortality as well as respiratory health care burden, according to a new study ...

Investigators conducted a retrospective study to determine the association between new-onset metabolic syndrome during the first year after initiation of concurrent androgen deprivation therapy and an ...

Researchers compared CPX-351 with standard induction therapy in children and young adults with newly diagnosed AML.

Researchers evaluated the efficacy of primary eye-preserving therapy versus primary enucleation in patients with early cT3c retinoblastoma.

Investigators reviewed literature to identify core domains for delivering complete decongestive therapy to patients with breast cancer.

Researchers evaluated nutrition impact symptoms in patients with gastric cancer receiving chemotherapy to identify distinct symptom burden profiles.

Burden is highest in men and correlates with some modifiable factors like smoking, body mass index, and occupational benzene/formaldehyde exposure.

The phase 1b/2 ELEVATE study evaluated everolimus, an mTORC1 inhibitor, plus elacestrant, a next-generation, oral selective ER degrader, in adult patients with ER+/HER2- breast cancer.

Investigators evaluated the efficacy and safety of immune checkpoint inhibitors in high-risk patients with genitourinary cancers and advanced chronic kidney disease.

In this analysis, researchers sought to assess the impact of the 21st Century Cures Act, which gave the FDA increased flexibility to accept a single pivotal trial as the basis for a novel drug ...

Phase 3 RASolute 302 data show daraxonrasib significantly extended overall and progression free survival compared with chemotherapy in metastatic PDAC.